Announced
Completed
Financials
Tags
Completed
Acquisition
Friendly
treatment development
Private
Single Bidder
United States
cancer treatment
Biotechnology
Domestic
Majority
Synopsis
Agilent, an American analytical instrumentation development and manufacturing company, completed the acquisition of Resolution Bioscience, a cancer diagnostics solutions provider, for $695m. "The Resolution Bioscience team and powerful technology are strategic and important additions to Agilent’s growing business in precision oncology solutions. This also accelerates our work to more broadly deliver precision oncology testing for patients worldwide with NGS-based diagnostic kits. We’re excited to have Resolution Bioscience joining with us to expand our work in the fight against cancer," Mike McMullen, Agilent President and CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.